{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:31:50Z","timestamp":1785540710172,"version":"3.56.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Bilateral adrenalectomy for congenital adrenal hyperplasia (CAH) has been a historical therapeutic option for carefully selected patients who have had unsatisfactory outcomes with conventional medical management, as well as those with large adrenal tumors and hyperplasia. Rarely, adrenalectomy is performed in an undiagnosed patient with CAH due to suspicion of adrenocortical cancer, and after the surgery CAH is diagnosed. However, there are fears of increased risk of adrenal crisis and growth of adrenal rest tumors post-adrenalectomy, especially after bilateral adrenalectomy. Moreover, an adrenalectomy is a quite extensive procedure. Now with the newly approved crinecerfont (a corticotropin-releasing factor type 1 receptor (CRF1) antagonist, approved by FDA in US December 2024), and the coming phase 3 study of atumelnant (a MC2R antagonist), the commenced phase 2 study of Lu AG13909 (an anti-ACTH monoclonal antibody) as well as the preclinical studies with OMass MC2R antagonist compounds, there may be new options to decrease the size of the adrenal tumors\/hyperplasia. Thus, these may be used instead of adrenalectomy. However, the cost of these new drugs may be very high so they may not become widely available, and adrenalectomy may prove to be more cost effective. This review will discuss the current use of adrenalectomy in patients with CAH and how the introduction of the new drugs may change it.<\/jats:p>","DOI":"10.3389\/fendo.2025.1693063","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:21:44Z","timestamp":1762320104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["What is the need for adrenalectomy in patients with congenital adrenal hyperplasia in the era of CRF1\/ACTH inhibitors?"],"prefix":"10.3389","volume":"16","author":[{"given":"Olga","family":"Fedorova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Falhammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S2213-8587(13)70007-X","article-title":"One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study","volume":"1","author":"Gidl\u00f6f","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12020-016-1189-x","article-title":"Clinical perspectives in congenital adrenal hyperplasia due to 11\u03b2-hydroxylase deficiency","volume":"55","author":"Bulsari","year":"2017","journal-title":"Endocrine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management","volume":"43","author":"Claahsen-Van Der Grinten","year":"2022","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0712","article-title":"Management of endocrine disease: diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency","volume":"180","author":"Nordenstr\u00f6m","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909786","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"383","author":"Merke","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000402","article-title":"Update on diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"25","author":"White","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4158\/EP151085.RA","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency presenting as adrenal incidentaloma: a systematic review and meta-analysis","volume":"22","author":"Falhammar","year":"2016","journal-title":"Endocr Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0731-6","article-title":"Biochemical and genetic diagnosis of 21-hydroxylase deficiency","volume":"50","author":"Falhammar","year":"2015","journal-title":"Endocrine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad134","article-title":"Interpretation of steroid biomarkers in 21-hydroxylase deficiency and their use in disease management","volume":"108","author":"Sarafoglou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2022.1528","article-title":"Long-term outcomes of congenital adrenal hyperplasia","volume":"37","author":"Nordenstr\u00f6m","year":"2022","journal-title":"Endocrinol Metab (Sel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/2042018818821294","article-title":"Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency","volume":"10","author":"Oprea","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0828","article-title":"Fertility, sexuality and testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia","volume":"166","author":"Falhammar","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-1093","article-title":"Management of endocrine disease: Gonadal dysfunction in congenital adrenal hyperplasia","volume":"184","author":"Claahsen-Van Der Grinten","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0862","article-title":"Sweep FC et\u00a0al; dsd-LIFE group. Gonadal function in adult male patients with congenital adrenal hyperplasia","volume":"178","author":"Engels","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae718","article-title":"Challenges in adolescent and adult males with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Claahsen-Van Der Grinten","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2018.1441399","article-title":"Para-ovarian adrenal rest tumors: gynecologic manifestations of untreated congenital adrenal hyperplasia","volume":"34","author":"Sisto","year":"2018","journal-title":"Gyn Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa870","article-title":"11C-Metomidate PET\/CT detected multiple ectopic adrenal rest tumors in a woman with congenital adrenal hyperplasia","volume":"106","author":"Burman","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2957","article-title":"Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"99","author":"Falhammar","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5748264","article-title":"Hospital admission patterns in children with CAH: admission rates and adrenal crises decline with age","volume":"2016","author":"Rushworth","year":"2016","journal-title":"Int J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.74.3.1311000","article-title":"Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia","volume":"74","author":"Jaresch","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2020-0058","article-title":"Prevalence and characteristics of adrenal tumors and myelolipomas in congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"26","author":"Nermoen","year":"2020","journal-title":"Endocr Pract"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00178-9","article-title":"Adrenal myelolipomas","volume":"9","author":"Calissendorff","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-008-9034-2","article-title":"Lack of ACTH and androgen receptor expression in a giant adrenal myelolipoma associated with 21-hydroxylase deficiency","volume":"19","author":"Hagiwara","year":"2008","journal-title":"Endocr Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-14-42","article-title":"Increased expression of ACTH (MC2R) and androgen (AR) receptors in giant bilateral myelolipomas from patients with congenital adrenal hyperplasia","volume":"14","author":"Almeida","year":"2014","journal-title":"BMC Endocr Disord"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-0162-1","article-title":"Non-functioning adrenal incidentalomas caused by 21-hydroxylase deficiency or carrier status","volume":"47","author":"Falhammar","year":"2014","journal-title":"Endocrine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3989","article-title":"11-oxygenated androgens are biomarkers of adrenal volume and testicular adrenal rest tumors in 21-hydroxylase deficiency","volume":"102","author":"Turcu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1017303","article-title":"Congenital adrenal hyperplasia is a very rare cause of adrenal incidentalomas in Sweden","volume":"13","author":"Sahlander","year":"2022","journal-title":"Front Endocrinol (Lus)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4158\/EP15618.OR","article-title":"Clinical outcomes in adrenal incidentaloma: experience from one center","volume":"21","author":"Patrova","year":"2015","journal-title":"Endocr Pract"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01933-0","article-title":"Congenital adrenal hyperplasia in patients with adrenal tumors: a population-based case-control study","volume":"46","author":"Sahlander","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.9.8784066","article-title":"The use of adrenalectomy as a treatment for congenital adrenal hyperplasia","volume":"81","author":"Van Wyk","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00217","article-title":"Bilateral adrenalectomy in congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"103","author":"MacKay","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2008.12.005","article-title":"Bilateral adrenalectomy for severe hypertension in congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency: long term follow-up","volume":"70","author":"Kacem","year":"2009","journal-title":"Ann Endocrinol (Par)"},{"key":"B35","article-title":"Congenital adrenal hyperplasia 11beta-hydroxylase deficiency: two cases managed with bilateral adrenalectomy","volume":"50","author":"John","year":"2009","journal-title":"Sg Med J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1807486","article-title":"Adrenal crisis","volume":"381","author":"Rushworth","year":"2019","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1530\/EJE-12-0161","article-title":"Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency","volume":"167","author":"Reisch","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/1687-9856-2012-2","article-title":"Physical, social and societal functioning of children with congenital adrenal hyperplasia (CAH) and their parents, in a Dutch population","volume":"2012","author":"Sanches","year":"2012","journal-title":"Int J Pediatr Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-022026","article-title":"The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia","volume":"88","author":"Van Wyk","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000295722","article-title":"Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hypersecretion following adrenalectomy","volume":"74","author":"Tiosano","year":"2010","journal-title":"Horm Res Paediatr"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2298","article-title":"Use of PET\/CT with cosyntropin stimulation to identify and localize adrenal rest tissue following adrenalectomy in a woman with congenital adrenal hyperplasia","volume":"97","author":"Crocker","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1515\/jpem.2005.18.1.97","article-title":"Adrenocorticotropin hypersecretion and pituitary microadenoma following bilateral adrenalectomy in a patient with classic 21-hydroxylase deficiency","volume":"18","author":"Charmandari","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s11102-021-01158-z","article-title":"Prevalence of Nelson\u2019s syndrome after bilateral adrenalectomy in patients with cushing\u2019s disease: a systematic review and meta-analysis","volume":"24","author":"Papakokkinou","year":"2021","journal-title":"Pituitary"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404656","article-title":"CAHtalyst adult trial investigators. Phase 3 trial of Crinecerfont in adult congenital adrenal hyperplasia","volume":"391","author":"Auchus","year":"2024","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae759","article-title":"Future directions in the management of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Sarafoglou","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab749","article-title":"Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia","volume":"107","author":"Auchus","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad270","article-title":"Crinecerfont, a CRF1 receptor antagonist, lowers adrenal androgens in adolescents with congenital adrenal hyperplasia","volume":"108","author":"Newfield","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2404655","article-title":"Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia","volume":"391","author":"Sarafoglou","year":"2024","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01089-w","article-title":"Recent advances in treatments for congenital adrenal hyperplasia","volume":"21","author":"Falhammar","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab438","article-title":"Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: results from two Phase 2 studies","volume":"106","author":"Sarafoglou","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","volume-title":"Spruce Biosciences announces topline results from CAHmelia-204 adult trial","year":"2024"},{"key":"B52","article-title":"A double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CRN04894 in healthy volunteers","volume-title":"ClinicalTrials.gov Identifier: NCT06048887","year":"2023"},{"key":"B53","doi-asserted-by":"publisher","first-page":"A83","DOI":"10.1210\/jendso\/bvac150.172","article-title":"Inhibition of basal and ACTH-stimulated cortisol secretion in humans using an oral nonpeptide ACTH antagonist (CRN04894)","volume":"6","author":"Betz","year":"2022","journal-title":"J Endocr Soc"},{"key":"B54","article-title":"A 12-week, phase 2 open-label, sequential dose cohort study to evaluate the safety, efficacy, and pharmacokinetics of CRN04894 treatment in participants with congenital adrenal hyperplasia (TouCAHn)","volume-title":"ClinicalTrials.gov Identifier: NCT05907291","year":"2023"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.249","article-title":"Once daily oral atumelnant (CRN04894) induces rapid and profound reductions of androstenedione and 17-hydroxyprogesterone in participants with classical congenital adrenal hyperplasia: initial results from a 12-week, phase 2, open-label study","volume":"8","author":"Auchus","year":"2024","journal-title":"J Endocr Soc"},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf149.408","article-title":"Rapid and sustained reduction of 11-oxygenated androgens in adults with classic congenital adrenal hyperplasia following once-daily oral atumelnant (CRN04894): results from a 12-week, Phase 2, open-label study","author":"Reisch","year":"2025"},{"key":"B57","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf149.320","article-title":"Reductions in adrenal volume in patients with congenital adrenal hyperplasia receiving once-daily oral atumelnant (CRN04894): interim results from a 12-week, Phase 2, open-label study","author":"Bachega","year":"2025"},{"key":"B58","volume-title":"Crinetics Pharmaceuticals reports progress on paltusotine NDA and atumelnant Phase 3 study amid strong financial position","year":"2025"},{"key":"B59","volume-title":"Crinetics to present new research on paltusotine, atumelnant and unmet needs in acromegaly treatment at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025","year":"2025"},{"key":"B60","volume-title":"Crinetics receives FDA Orphan Drug Designation for atumelnant in the treatment of congenital adrenal hyperplasia (CAH)","year":"2025"},{"key":"B61","doi-asserted-by":"publisher","first-page":"A12484","DOI":"10.1210\/jendso\/bvae163.285","article-title":"Safety and pharmacokinetics of anti-acth antibody Lu AG13909 in patients with classic congenital adrenal hyperplasia: phase 1 open-label, multiple-ascending-dose trial protocol","volume":"8","author":"Srirangalingam","year":"2024","journal-title":"J Endocr Soc"},{"key":"B62","article-title":"A multi-site, open-label, sequential-group, multiple-dose trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of Lu AG13909 in participants with congenital adrenal hyperplasia","volume-title":"ClinicalTrials.gov Identifier: NCT05669950","year":"2023"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf149.226","article-title":"A novel anti-ACTH antibody Lu AG13909 in clinical development for treatment of classic congenital adrenal hyperplasia: a phase 1 open-label, multiple-ascending-dose study","author":"Johannsson","year":"2025"},{"key":"B64","article-title":"Optimizing binding kinetics to develop insurmountable MC2 receptor antagonists for the treatment of congenital adrenal hyperplasia","author":"Malet Sanz","year":"2025"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1693063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:21:47Z","timestamp":1762320107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1693063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":64,"alternative-id":["10.3389\/fendo.2025.1693063"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1693063","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1693063"}}